Chronic Obstructive Pulmonary DiseaseNCT04683952
Rehabilitation With HHFNC in COPD in Nocturnal NIV
A study testing Exercise training with Humified High Flow Nasal Cannula in people with Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.
Trial summary
Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease
- What is being tested?
- Exercise training with Humified High Flow Nasal Cannula
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jan 2020to Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Chronic Obstructive Pulmonary Disease (post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) <0.7) ;
- Nocturnal Non Invasive Ventilation (NIV) prescription according to ATS/ERS guidelines with or without long-term oxygen therapy;
- Clinical stability (no exacerbation and no changing in respiratory drugs in the last 7 days);
Who cannot join
- Orthopedic or neurological pathologies that limit physical performance;
- Cognitive impairment (Mini-Mental State Examination <24);
- Advanced heart disease, pulmonary fibrosis, participation in other clinical studies in the six months preceding the start of the study.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
IRCCS Santa Maria Nascente, Fondazione Don Carlo Gnocchi
Milan, 20148
Paolo Banfi, MD, 0240308812 ext. 0039, pabanfi@dongnocchi.it
Laila Di Pietro, RT, 024038570 ext. 0039, ldipietro@dongnocchi.it
About this study
Official title: Efficacy of Exercise Training With Humified High Flow Nasal Cannula, in Patients With Chronic Obstructive Pulmonary Disease Already in Nocturnal Non-Invasive Ventilation
Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non Invasive Ventilation (NIV) and provide heated and humidified gas. HHFNC is mainly used in intensive care settings or in acute respiratory diseases for the treatment of mild to moderate acute hypoxic respiratory failure and ventilator weaning. The aim of this study is to evaluate, in patients with Chronic Obstructive Pulmonary Disease (COPD) in nocturnal NIV, according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines, whether HHFNC during rehabilitation has an additional effect in increasing the distance in 6 Minute Walking Distance (6MWD) compared to the control group with nocturnal NIV without HHFNC treatment. As secondary objectives, we expect a decrease in Emergency Department (ED) accesses, General Practitioner (GP) unplanned visits, hospitalizations and an improvement of the quality of life and patient satisfaction.
Read the detailed description
RECRUITMENT PHASE: A qualified physiotherapist will check patient lists daily with the aim of identifying suitable candidates for the study.
The patients will be enrolled from January 2020 till june 2021 and they will be stratified individually and randomized by a dedicated software (https://www.randomizer.org/) into two groups:
- Experimental group - Chronic Obstructive Pulmonary Disease (COPD) patients in nocturnal Non Invasive Ventilation (NIV) underwent to respiratory rehabilitation with Humidified High Flow Nasal Cannula (HHFNC) with / without Oxygen Therapy (O2), according to medical prescription;
- Control group - patients in nocturnal NIV underwent to respiratory rehabilitation without HFNC with / without O2, according to medical prescription.
Before randomization, individual clinical inclusion and exclusion criteria will be taken into account in relation to the ability of each patient to tolerate the administration of the high flow ventilation program foreseen by the study.
RUN IN PHASE: After the assessment, each patient will perform a training session prior to the cycle ergometer, during which the subject will work on the workload and the established flow. The intensity of the workload will be 60-80% of the Wmax, calculated with the Hill's formula:
Wmax = ( 0.122 x 6MWD) + (72, 683 x Height) - 117.109
(where 6MWD is the distance walked on the 6-minute walk test, and the patient's height must be expressed in meters).
NIV and HHFNC will be administered through VEMO 150 (EOVE SA. 64000 Pau - France), a device with which it is possible setting up to 4 different ventilation programs. The High Flow can be delivered, as a continuous flow through the humidified nasal cannulas, up to 60 L / min with or without additional oxygen therapy according to medical prescription. The patients of the experimental group will be trained with the most adequate continuous flow, in a range between 20 and 60 L/min, according to the maximum flow supported by the patient.
FOLLOW UP PHASE: Outpatient rehabilitation will be performed in 3 cycles, each cycle in 40-minute sessions, 3 times a week. Each session starts with the cycle ergometer with a 5-minute warm-up to an intensity of 0 watts, continues with a 30-minute resistance training phase at a continuous target intensity (60-80% Wmax), then a warm-down of 5 minutes at an intensity of 0 watts.
The rehabilitation will be followed by a three-month washout period, for 3 cycles.
MEASUREMENTS: We have identified four periods to evaluate gas exchange, Forced expiratory volume in one second (FEV1) and respiratory muscle strength, dyspnea, exercise capacity, the presence of obstructive/central sleep apnea, prediction of mortality, activities of daily life, the impact of the disease and the quality of life.
These four periods are:
- T0: baseline;
- T1: at the end of the first rehabilitation cycle;
- T2: at the end of the second rehabilitation cycle;
- T3: at the end of the third rehabilitation cycle.
At the beginning of the study, demographics and clinical characteristics of eligible study participants will be collected.
Patients will be evaluated for:
- Blood gas analysis (BGA) in T0, T1, T2, T3;
- Spirometry: Forced Vital Capacity (FVC), FEV1 and FEV1/FEVC% in T0, T3;
- Questionnaire of the British Medical Research Council (MRC) modified, in T0, T1, T2, T3;
- Basic / Transition Dyspnea Index (BDI / TDI), in T0, T1, T2, T3;
- 6 Minute Walking Distance (6MWD) with / without oxygen therapy, according to the medical prescription during the effort, in T0, T1, T2, T3;
- COPD Assessment Test (CAT) in T0, T1, T2, T3;
- Night time Polygraph to detect apnea/hypopnea, in T0, T3 ;
- BODE INDEX (where BODE means body mass index, obstruction of air flow, dyspnoea and exercise capacity), in order to estimate the probability of survival, in T0, T1, T2, T3;
- Saint George Respiratory Questionnaire (SGRQ) to investigate the quality of life in T0 and T3;
- Evaluation of the perception of muscle fatigue and dyspnea (Borg RPE) and Visual Analogue Scale (VAS) each session.
During training, and the run-in phase, the physiotherapist will take note of FiO2 and of the dyspnea at the beginning and end of the session through VAS / BORG and again when the patient will be evaluated in 6MWD).
- Conditions
- Chronic Obstructive Pulmonary Disease
- Being tested
- Exercise training with Humified High Flow Nasal Cannula, Exercise training - Control Group
- Keywords
- COPD, HHFNC, Chronic Obstructive Pulmonary Disease, Humidified High Flow Nasal Cannula, Non Invasive Ventilation
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise training with Humified High Flow Nasal CannulaDevice
Also called VEMO 150
The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
Exercise training - Control GroupOther
The control group will perform exercise training in spontaneous breathing.
| Study group | Role | What they receive |
|---|---|---|
| Rehabilitation with HHFNC | Experimental | 15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).
The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. Receives: Device: Exercise training with Humified High Flow Nasal Cannula |
| Control Group rehabilitation without HHFNC | Active comparator | 15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).
The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. Receives: Other: Exercise training - Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in 6MWD
The first outcome we expect to find is a change in the distance at 6-Minute Walking Distance (6MWD).
Measured: "Baseline ( pre-intervention)" and "Immediately after the intervention".
Secondary outcomes (1)
Number of Exacerbations, GP visits and admission to ED and ICU
The second outcome is change of COPD exacerbation as admission to the Intensive Care Unit (ICU), to the admission to the ED with/without hospitalization, Generale Practitioner (GP) unplanned visits.
Measured: Through study completion, an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2020
- Study start1 Jan 2020
- Primary completionJan 2021 (estimated)
- Study completionJan 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- More trials run by Fondazione Don Carlo Gnocchi ETSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETS
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paolo Banfi, MD, Principal investigator, Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria NascenteLaila Di Pietro, RT, Study chair, Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria Nascente
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04683952
- Sponsor's protocol ID
- FDG_HFNC_COPD_01
- Status last verified
- May 2020
- First submitted
- 21 May 2020
- Last updated
- 24 Dec 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014 Aug 7;14:66. doi: 10.1186/1471-2253-14-66. eCollection 2014.
PubMed 25110463Stephan F, Berard L, Rezaiguia-Delclaux S, Amaru P; BiPOP Study Group. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017 Sep;62(9):1193-1202. doi: 10.4187/respcare.05473. Epub 2017 Aug 14.
PubMed 28807988Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7. doi: 10.1016/j.apmr.2008.01.020.
PubMed 18760164Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. Print 2019 Sep.
PubMed 31467119
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Exercise Training With Humified High Flow Nasal Cannula, in Patients With Chronic Obstructive Pulmonary Disease Already in Nocturnal Non-Invasive Ventilation
- ClinicalTrials.gov ID
- NCT04683952
- Acronym / sponsor ID
- FDG_HFNC_COPD_01
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- COPD, HHFNC, Chronic Obstructive Pulmonary Disease, Humidified High Flow Nasal Cannula, Non Invasive Ventilation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETSUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- Jan 2021 (estimated)
- Study completion
- Jan 2022 (estimated)
- First posted
- 24 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non Invasive Ventilation (NIV) and provide heated and humidified gas. HHFNC is mainly used in intensive care settings or in acute respiratory diseases for the treatment of mild to moderate acute hypoxic respiratory failure and ventilator weaning. The aim of this study is to evaluate, in patients with Chronic Obstructive Pulmonary Disease (COPD) in nocturnal NIV, according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines, whether HHFNC during rehabilitation has an additional effect in increasing the distance in 6 Minute Walking Distance (6MWD) compared to the control group with nocturnal NIV without HHFNC treatment. As secondary objectives, we expect a decrease in Emergency Department (ED) accesses, General Practitioner (GP) unplanned visits, hospitalizations and an improvement of the quality of life and patient satisfaction.
Detailed description
RECRUITMENT PHASE: A qualified physiotherapist will check patient lists daily with the aim of identifying suitable candidates for the study.
The patients will be enrolled from January 2020 till june 2021 and they will be stratified individually and randomized by a dedicated software (https://www.randomizer.org/) into two groups:
- Experimental group - Chronic Obstructive Pulmonary Disease (COPD) patients in nocturnal Non Invasive Ventilation (NIV) underwent to respiratory rehabilitation with Humidified High Flow Nasal Cannula (HHFNC) with / without Oxygen Therapy (O2), according to medical prescription;
- Control group - patients in nocturnal NIV underwent to respiratory rehabilitation without HFNC with / without O2, according to medical prescription.
Before randomization, individual clinical inclusion and exclusion criteria will be taken into account in relation to the ability of each patient to tolerate the administration of the high flow ventilation program foreseen by the study.
RUN IN PHASE: After the assessment, each patient will perform a training session prior to the cycle ergometer, during which the subject will work on the workload and the established flow. The intensity of the workload will be 60-80% of the Wmax, calculated with the Hill's formula:
Wmax = ( 0.122 x 6MWD) + (72, 683 x Height) - 117.109
(where 6MWD is the distance walked on the 6-minute walk test, and the patient's height must be expressed in meters).
NIV and HHFNC will be administered through VEMO 150 (EOVE SA. 64000 Pau - France), a device with which it is possible setting up to 4 different ventilation programs. The High Flow can be delivered, as a continuous flow through the humidified nasal cannulas, up to 60 L / min with or without additional oxygen therapy according to medical prescription. The patients of the experimental group will be trained with the most adequate continuous flow, in a range between 20 and 60 L/min, according to the maximum flow supported by the patient.
FOLLOW UP PHASE: Outpatient rehabilitation will be performed in 3 cycles, each cycle in 40-minute sessions, 3 times a week. Each session starts with the cycle ergometer with a 5-minute warm-up to an intensity of 0 watts, continues with a 30-minute resistance training phase at a continuous target intensity (60-80% Wmax), then a warm-down of 5 minutes at an intensity of 0 watts.
The rehabilitation will be followed by a three-month washout period, for 3 cycles.
MEASUREMENTS: We have identified four periods to evaluate gas exchange, Forced expiratory volume in one second (FEV1) and respiratory muscle strength, dyspnea, exercise capacity, the presence of obstructive/central sleep apnea, prediction of mortality, activities of daily life, the impact of the disease and the quality of life.
These four periods are:
- T0: baseline;
- T1: at the end of the first rehabilitation cycle;
- T2: at the end of the second rehabilitation cycle;
- T3: at the end of the third rehabilitation cycle.
At the beginning of the study, demographics and clinical characteristics of eligible study participants will be collected.
Patients will be evaluated for:
- Blood gas analysis (BGA) in T0, T1, T2, T3;
- Spirometry: Forced Vital Capacity (FVC), FEV1 and FEV1/FEVC% in T0, T3;
- Questionnaire of the British Medical Research Council (MRC) modified, in T0, T1, T2, T3;
- Basic / Transition Dyspnea Index (BDI / TDI), in T0, T1, T2, T3;
- 6 Minute Walking Distance (6MWD) with / without oxygen therapy, according to the medical prescription during the effort, in T0, T1, T2, T3;
- COPD Assessment Test (CAT) in T0, T1, T2, T3;
- Night time Polygraph to detect apnea/hypopnea, in T0, T3 ;
- BODE INDEX (where BODE means body mass index, obstruction of air flow, dyspnoea and exercise capacity), in order to estimate the probability of survival, in T0, T1, T2, T3;
- Saint George Respiratory Questionnaire (SGRQ) to investigate the quality of life in T0 and T3;
- Evaluation of the perception of muscle fatigue and dyspnea (Borg RPE) and Visual Analogue Scale (VAS) each session.
During training, and the run-in phase, the physiotherapist will take note of FiO2 and of the dyspnea at the beginning and end of the session through VAS / BORG and again when the patient will be evaluated in 6MWD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rehabilitation with HHFNC | Experimental | Device: Exercise training with Humified High Flow Nasal Cannula15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. |
| Control Group rehabilitation without HHFNC | Active comparator | Other: Exercise training - Control Group15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosis of Chronic Obstructive Pulmonary Disease (post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) <0.7) ;
- Nocturnal Non Invasive Ventilation (NIV) prescription according to ATS/ERS guidelines with or without long-term oxygen therapy;
- Clinical stability (no exacerbation and no changing in respiratory drugs in the last 7 days);
Key exclusion criteria (3 listed)
- Orthopedic or neurological pathologies that limit physical performance;
- Cognitive impairment (Mini-Mental State Examination <24);
- Advanced heart disease, pulmonary fibrosis, participation in other clinical studies in the six months preceding the start of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise training with Humified High Flow Nasal CannulaAlso: VEMO 150The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min. | Device | Rehabilitation with HHFNC |
| Exercise training - Control GroupThe control group will perform exercise training in spontaneous breathing. | Other | Control Group rehabilitation without HHFNC |
Primary outcome
Change from baseline in 6MWD
Time frame: "Baseline ( pre-intervention)" and "Immediately after the intervention".
The first outcome we expect to find is a change in the distance at 6-Minute Walking Distance (6MWD).
1 secondary outcome
Number of Exacerbations, GP visits and admission to ED and ICU
Time frame: Through study completion, an average of 1 year.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2020.
- Background: PubMed 25110463Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014 Aug 7;14:66. doi: 10.1186/1471-2253-14-66. eCollection 2014.
- Background: PubMed 28807988Stephan F, Berard L, Rezaiguia-Delclaux S, Amaru P; BiPOP Study Group. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017 Sep;62(9):1193-1202. doi: 10.4187/respcare.05473. Epub 2017 Aug 14.
- Background: PubMed 18760164Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7. doi: 10.1016/j.apmr.2008.01.020.
- Background: PubMed 31467119Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. Print 2019 Sep.
- The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary DiseaseLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paolo Banfi, MD principal investigator
Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria Nascente
Laila Di Pietro, RT study chair
Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria Nascente
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise training with Humified High Flow Nasal Cannula in people with Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Paolo Banfi, MD (02 40308812, pabanfi@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in 6MWD (time frame: "Baseline ( pre-intervention)" and "Immediately after the intervention".). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04683952, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2020.